Authors
Achille Marino, Dariush Khaleghi Hashemian, Claudia Iannone, Cristina Bochicchio, Marco Pandolfi, Giovanna Lommano, Stefania Costi, Francesco Baldo, Federico Rissotto, Costanza Barresi, Valeria Carla Edefonti, Federico Ambrogi, Roberto Caporali, Elisabetta Miserocchi, Cecilia Beatrice Chighizola
Published in
Expert opinion on biological therapy. Jun 28, 2026. Epub Jun 28, 2026.
Abstract
To assess prescription patterns and describe the long-term real-life effectiveness of different TNF inhibitors (TNFi) in juvenile idiopathic arthritis related uveitis (JIA-U).
Patients with JIA-U treated with TNFi were retrospectively enrolled.
96 JIA-U patients (77% female) with an age at diagnosis of 2.44 [interquartile range (IQR) 1.56-3.81] and a median follow-up of 19 years were included. Adalimumab was the most frequently prescribed TNFi (61%), followed by etanercept (19%), infliximab (15%) and golimumab (5%). Overall, adalimumab showed the lowest complications rate (51%; p < 0.001) and median number of uveitis relapse (1; IQR 0-2; p = 0.012). Conversely etanercept showed the highest median number of uveitis relapses (4; IQR 1-5). The cumulative incidences curves for 'uveitis relapse' were similar among TNFi. Conversely, when 'treatment change' was considered as the event, a significantly higher risk for patients treated with infliximab compared with those receiving adalimumab emerged (HR 3.06, 95% CI 1.41-6.63; p < 0.01).
All TNFi appear to be effective for long-term management of JIA-U. We observed some differences in number of uveitis relapses and ocular complication rates favoring adalimumab over infliximab and etanercept, findings to be further confirmed in prospective studies.
PMID:
42365450
Bibliographic data and abstract were imported from PubMed on 28 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0